Author

Christopher Gasink 1

1 Janssen Scientific Affairs, LLC,Horsham,United States

Identification of risk factors associated with loss of response to ustekinumab in Crohn's disease

Steve Hanauer, Bruce E. Sands, Brian G. Feagan, A Oortwijn, Roger van Kruchten, Victor Laliman, James Izanec, Joseph Adedokun, Long-Long Gao, Sheldon Sloan, Christopher Gasink, S Targan, Willem de Villiers, Paul Rutgeerts, Jean-Frédéric Colombel, Subrata Ghosh

Immunogenicity of Ustekinumab in Patients with Crohn's Disease: Results from the IM-UNITI Study

William Sandborn, Bruce E. Sands, Jeannette Nussbaum, A Oortwijn, Christopher Gasink, Douglas Jacobstein, Long-Long Gao, Omoniyi J. Adekokun, Willem de Villiers, Subrata Ghosh

RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES

Jean-Frederic Colombel, Sheldon Sloan, Christopher Gasink, Long-Long Gao, Douglas Jacobstein, Scott D. Lee, Stephan Targan

ROLE OF CONCOMITANT IMMUNOSUPPRESSION IN THE EFFICACY AND SAFETY OF USTEKINUMAB: POST-HOC ANALYSES OF UNITI

Subrata Ghosh, Bernie Sattin, Douglas Jacobstein, L.L. Gao, Christopher Gasink, Paul Rutgeerts, Stephen B Hanauer

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

Silvio Danese, Millie Long, Elyssa Ott, Christopher Gasink, Thomas Baker, Ye Miao, Ilia Tikhonov, Proton Rahman, Edward V. Loftus, Bruce Strober

Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results from Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis

Subrata Ghosh, Bruce E. Sands, Christopher D. O'Brien, Ilia Tikhonov, Yiying Zhou, Sheri Volger, Colleen W. Marano, Elyssa Ott, Christopher Gasink, William Sandborn, Silvio Danese

SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (≥60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

Subrata Ghosh, Elyssa Ott, Christopher Gasink, Ye Miao, Colleen W. Marano, John Lynch, Maria T. Abreu, Aline Charabaty

THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY

Silvio Danese, James Izanec, Tony Ma, Omoniyi J. Adedokun, Christopher Gasink, Stephen B Hanauer, Ellen Scherl, Kamal Patel

USTEKINUMAB IMPROVES PRODUCTIVITY AND REDUCES WORK LIMITATION OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THREE PHASE 3 CLINICAL TRIALS

Bruce E. Sands, Chenglong Han, Dominik Naessens, Christopher Gasink, Douglas Jacobstein, L.L. Gao, Brian G. Feagan

USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS    

William Sandborn, Benjamin Yeager, Christopher Gasink, Timothy Hoops, Long-Long Gao, Yanli Wang, Douglas Jacobstein, Scott D. Lee, Stephen B Hanauer

Item 11 - 20 / 20
1
2